Exercise of Warrants
Sareum Holdings PLC announced the exercise of warrants to subscribe for 825,000 new ordinary shares at 12.5 pence per share, resulting in a total consideration of £103,125 for the company. Application has been made for admission of these shares to trading on AIM, expected around September 24, 2025. Following admission, the total number of ordinary shares in issue will be 138,044,973, representing the total number of voting rights.
Select text to share a quote on X · sign in to keep highlights & notes in your SAR notes
Cambridge, UK, 18 September 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has received notices to exercise certain warrants to subscribe for a total of 825,000 new ordinary shares in the capital of the Company at a price of 12.5 pence per ordinary share ("New Ordinary Shares") for a total consideration to the Company of £103,125.
Admission and Total Voting Rights
Application has been made to the London Stock Exchange plc for the admission of the 825,000 New Ordinary Shares to trading on AIM ("Admission"). It is expected that Admission will occur at 8.00 a.m. (London time) on or around Wednesday 24 September 2025. The New Ordinary Shares will rank pari passu with the existing ordinary shares.
Immediately following Admission, the total number of ordinary shares in issue will be 138,044,973. and the total number of voting rights will therefore be 138,044,973, and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.